Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 18/20 | 0.73 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6429466 | 0.77 | MME (0.72) | MME | |
| SCHEMBL4201407 | 0.77 | TAS1R3 (1.00) | TAS1R3TAS1R1 | |
| SCHEMBL7171776 | 0.74 | MME (0.67) | MME | |
| SCHEMBL7447903 | 0.73 | MME (1.00) | MME | |
| SCHEMBL6431930 | 0.73 | MME (1.00) | MME | |
| SCHEMBL7446023 | 0.72 | MME (0.68) | MME | |
| SCHEMBL5923977 | 0.70 | TAS1R3 (0.68) | TAS1R3TAS1R1 | |
| SCHEMBL7452539 | 0.69 | MME (1.00) | MME | |
| SCHEMBL7450720 | 0.69 | MME (1.00) | MME | |
| SCHEMBL5924004 | 0.68 | TAS1R3 (0.64) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070499-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050020547-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1097719-B1 | NEP inhibitors for the treatment of female sexual dysfunction | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040254153-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
| EP-1481667-A1 | NEP inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-6734186-B1 | PHOSPHODIESTERASE 2 INHIBITOR | PFIZER INC. | 2004-05-11 | — | — | US | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1097719-A1 | NEP inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097718-A1 | NPY antagonists for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097706-A1 | Phosphodiesterase inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254153-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | MME 2886/4885TAS1R3 2613/4885TAS1R1 2811/4885 |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | MME 7/4885TAS1R3 2798/4885TAS1R1 2600/4885 |
| US-20050020547-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | MME 2886/4885TAS1R3 2613/4885TAS1R1 2811/4885 |
| US-20050070499-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | MME 2886/4885TAS1R3 2613/4885TAS1R1 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.